Hims & Hers initiated with an Overweight at JPMorgan

JPMorgan analyst Cory Carpenter initiated coverage of Hims & Hers with an Overweight rating and $35 price target Hims is a leading direct-to-consumer healthcare platform with 2.5M subscribers across specialties including weight loss, women’s health, erectile dysfunction, hair loss, testosterone, and a growing number of international markets, the analyst tells investors in a research note. JPMorgan believes the company’s recent partnership with Novo Nordisk “could mark a turning point,” removing a significant legal overhang and positioning Hims & Hers as a platform that offers branded, generic, and compounded products.